Canada markets closed

XTL Biopharmaceuticals Ltd. (XTLB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8100+0.1100 (+4.07%)
At close: 04:00PM EDT
2.7200 -0.09 (-3.20%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.7000
Open2.6400
Bid2.7700 x 600
Ask2.8600 x 100
Day's Range2.5600 - 2.8300
52 Week Range0.7500 - 4.9900
Volume232,811
Avg. Volume742,100
Market Cap15.312M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.4000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    XTL To Aquire The Social Proxy

    expands its IP portfolio to AI Web Data The Social Proxy is a web data AI companydeveloping and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd., (the “Social Proxy”) a cutting edge web data company, developing and powering a unique ethical, IP

  • GlobeNewswire

    XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

    Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren’s syndrome, or SS, today addressed the status of the Company's continued and uninterrupted activity in Israel against the background of the recent severe terrorist attack in the south o

  • GlobeNewswire

    XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren’s syndrome, or SS, today announced that the Company received a written notification (the "Notice") from the Nasdaq Stock Market LLC (“Nasdaq”) on October 18, 2023, notifying the Company